{"id":"NCT01429441","sponsor":"ThromboGenics","briefTitle":"Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole","officialTitle":"A Randomized, Sham-controlled, Double-masked, Multicenter Study Evaluating Ocriplasmin Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-10","primaryCompletion":"2014-10","completion":"2014-10","firstPosted":"2011-09-07","resultsPosted":"2016-01-11","lastUpdate":"2016-03-14"},"enrollment":220,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Vitreomacular Adhesion Including Macular Hole"],"interventions":[{"type":"DRUG","name":"Ocriplasmin","otherNames":[]},{"type":"OTHER","name":"Sham injection","otherNames":[]}],"arms":[{"label":"Ocriplasmin","type":"EXPERIMENTAL"},{"label":"Sham injection","type":"SHAM_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the treatment of symptomatic vitreomacular adhesion / (VMT) including macular hole with ocriplasmin.","primaryOutcome":{"measure":"Proportion of Subjects With Pharmacological Vitreomacular Adhesion (VMA) / (Vitreomacular Traction [VMT]) Resolution at Day 28","timeFrame":"Day 28","effectByArm":[{"arm":"Ocriplasmin","deltaMin":41.7,"sd":null},{"arm":"Sham","deltaMin":6.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":9},"locations":{"siteCount":25,"countries":["United States"]},"refs":{"pmids":["34250257","30350717"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":49,"n":146},"commonTop":["Vitreous floaters","Color vision tests abnormal","Photopsia","Ophthalmological examination abnormal","Visual acuity reduced"]}}